The US FDA has approved crinecerfont for use alongside glucocorticoids to control androgen levels in adults and pediatric patients aged four and older with classic congenital adrenal hyperplasia. Crinecerfont, a corticotropin-releasing factor type 1 receptor antagonist, inhibits adrenocorticotropic hormone secretion from the pituitary and thus reduces adrenal androgen production. Clinical evidence The safety and efficacy of crinecerfont were evaluated in clinical trials involving 182 adults and 103 patients with congenital adrenal hyperplasia.
In these trials, crinecerfont significantly reduced daily glucocorticoid dose in adult and pediatric patients by 27% and 18%, respectively, while maintaining control of androstenedione. Dosage and administration Available as capsules Adults – 100 mg orally, twice daily with a meal Pediatric patients – Weight-based dosage orally, twice daily with a…
